Study Links GLP-1 Medications to Nutritional Deficiencies in Children
Children prescribed GLP-1 medications, such as Victoza, Saxenda, Trulicity, and Ozempic, for weight loss, prediabetes, or type 2 diabetes, may face significant nutritional risks. A new study published in the journal Childhood Obesity reveals that nearly one in six young patients (16.8%) were diagnosed with a nutritional deficiency within the first year of starting treatment. The most common deficiency identified was vitamin D, affecting 12.4% of the children involved in the study. As the use of GLP-1 medications becomes more prevalent in pediatric care, it is crucial to understand the potential risks during periods of rapid growth and development. Senior author Justin Ryder, PhD, who serves as the Vice Chair of Research at Ann & Robert H. Lurie Children's Hospital of Chicago and is also an Associate Professor at Northwestern University Feinberg School of Medicine, emphasizes the importance of monitoring nutrient intake during adolescence. Nutrients such as vitamin D, iron, and calcium are particularly vital during this stage, as deficiencies can have lasting effects on skeletal health and overall development. Adolescence is a time when the body requires substantial nutritional support for bone growth and other significant biological changes. The study's findings suggest that the impact of GLP-1 medications on appetite and food intake necessitates a heightened focus on nutritional care for younger patients. Alarmingly, the research indicated that only 5% of the children received nutritional counseling within 30 days of starting GLP-1 treatment, and fewer than 25% received such counseling within six months. To investigate this issue, Dr. Ryder and his team analyzed national administrative claims data from 2017 to 2022, which included over 100 million patients. They identified 2,031 GLP-1 users aged 10 to 17 who met the study's continuous enrollment criteria and had no prior diagnoses of nutritional deficiencies. Among these patients, liraglutide (Victoza and Saxenda) was the most commonly prescribed GLP-1 medication, accounting for 78.6% of prescriptions, followed by dulaglutide (Trulicity) at 10.4% and semaglutide (Ozempic and Wegovy) at 9.1%. The researchers advocate for the initiation of nutritional support alongside GLP-1 treatment rather than waiting for deficiencies to be diagnosed. Dr. Ryder hopes that the study's findings will raise awareness about the importance of proactive nutritional management when prescribing GLP-1 medications to children, emphasizing that understanding the risks allows for better prevention of harm during a critical developmental phase.




